Recent Updates
Recently added Catalysts

Risperdal Consta

Phase 3

Bipolar Disorder | Small molecule | Psychiatry |Johnson & Johnson|Last Updated: Jul 29, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment834
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00132678A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood EpisodesPHASE3 COMPLETED 559Feb 1, 2005Dec 1, 2007Jul 29, 201351 United States, Austria +8
NCT00094926A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.PHASE3 COMPLETED 275May 1, 2004Feb 1, 2007May 19, 2011 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Who Had a Mood Relapse.
24 months

Mood Relapse was defined as: The subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score \>12 or a CGI-S score \>4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.

Efficacy will be determined by measuring the time (in days) from randomization to event/relapse; relapse will be assessed by clinical status, rating scale changes, and pharmacologic stability in double-blind phase.
52 weeks
Secondary Endpoints
Change in Young Mania Rating Scale (YMRS) Scores.
Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV
Change in Montgomery-Åsberg Depression Rating Scale (MADRS)
Baseline and Endpoint (last observation carried forward) of 24 month Double-Blind Period IV
Safety and tolerability as assessed by adverse event reports (every 2 weeks), scores on movement disorder measures, laboratory parameters, vital signs, ECG measures and physical examination reports (every 2-3 months)
52 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
001EXPERIMENTALRisperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
002PLACEBO_COMPARATORPlacebo Matching placebo intramuscular (IM) injection every 2 weeks
Interventions
NameTypeDescription
Risperdal ConstaDRUG12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
PlaceboDRUGMatching placebo intramuscular (IM) injection every 2 weeks
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites51

Inclusion Criteria: * Diagnosis of bipolar 1 disorder, currently experiencing a mixed or manic episode or stable * Two or more bipolar mood episodes in the last 2 years excluding current episode * Negative pregnancy test Exclusion Criteria: * History of \> than 4 mood episodes a year during the l...

Countries:United StatesAustriaIndiaMalaysiaPolandRussiaSlovakiaSpainTaiwanUkraine
Unlock Eligibility Criteria